BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 17418938)

  • 1. Outcome of prostate cancer patients with initial PSA> or =20 ng/ml undergoing radical prostatectomy.
    Zwergel U; Suttmann H; Schroeder T; Siemer S; Wullich B; Kamradt J; Lehmann J; Stoeckle M
    Eur Urol; 2007 Oct; 52(4):1058-65. PubMed ID: 17418938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
    BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy.
    Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H
    J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy.
    Bianco FJ; Scardino PT; Stephenson AJ; Diblasio CJ; Fearn PA; Eastham JA
    Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):448-53. PubMed ID: 15890586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
    Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
    Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era.
    Gjertson CK; Asher KP; Sclar JD; Goluboff ET; Olsson CA; Benson MC; McKiernan JM
    Urology; 2007 Oct; 70(4):723-7. PubMed ID: 17991544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database.
    King CR; Freedland SJ; Terris MK; Kane CJ; Amling CL; Aronson WJ; Presti JC
    Urology; 2007 May; 69(5):921-6. PubMed ID: 17482935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression?
    Pfitzenmaier J; Pahernik S; Tremmel T; Haferkamp A; Buse S; Hohenfellner M
    BJU Int; 2008 Nov; 102(10):1413-8. PubMed ID: 18537951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
    Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
    Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of surgical margin status for biochemical recurrence following radical prostatectomy.
    Hashimoto K; Masumori N; Takei F; Fukuta F; Takahashi A; Itoh N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2008 Jan; 38(1):31-5. PubMed ID: 18203710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95.
    Wiegel T; Bottke D; Steiner U; Siegmann A; Golz R; Störkel S; Willich N; Semjonow A; Souchon R; Stöckle M; Rübe C; Weissbach L; Althaus P; Rebmann U; Kälble T; Feldmann HJ; Wirth M; Hinke A; Hinkelbein W; Miller K
    J Clin Oncol; 2009 Jun; 27(18):2924-30. PubMed ID: 19433689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
    Urology; 2007 Apr; 69(4):732-7. PubMed ID: 17445660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is an independent predictor of prostate-specific antigen failure after radical prostatectomy in patients with pT3aN0 prostate cancer.
    Yamamoto S; Kawakami S; Yonese J; Fujii Y; Ohkubo Y; Suyama T; Komai Y; Kijima T; Ishikawa Y; Fukui I
    Int J Urol; 2008 Oct; 15(10):895-9. PubMed ID: 18721204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radical prostatectomy for clinical stage T3a disease.
    Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
    Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.